Boston Scientific Announces Executive and Director Changes
Ticker: BSX · Form: 8-K · Filed: Sep 4, 2025 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $705,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: BSX
TL;DR
BSX board shakeup and exec comp changes filed. Watch for new strategy.
AI Summary
Boston Scientific Corporation (BSX) announced on August 29, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory plans for key executives. Specific details on the individuals involved and the financial implications of these compensation changes are outlined within the report.
Why It Matters
Changes in executive and director roles can signal shifts in company strategy or governance, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically carries a lower immediate risk compared to financial distress or major operational disruptions.
Key Players & Entities
- BOSTON SCIENTIFIC CORP (company) — Registrant
- August 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 300 Boston Scientific Way (address) — Business and mailing address
- Marlborough (city) — Business and mailing city
- Massachusetts (state) — Business and mailing state
FAQ
What specific roles have been affected by the departure of certain officers?
The filing indicates departures of certain officers, but the specific roles are not detailed in the provided excerpt. Further review of the full document would be needed for specifics.
Who are the newly elected directors?
The filing mentions the election of directors, but their names are not provided in this excerpt. The full report would contain this information.
What are the key changes in compensatory arrangements for certain officers?
The filing states there are updates to compensatory arrangements for certain officers, but the details of these changes are not specified in the provided text.
What is the effective date of these reported changes?
The earliest event reported is dated August 29, 2025.
What is Boston Scientific Corporation's standard industrial classification?
Boston Scientific Corporation's standard industrial classification is SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841].
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-09-04 16:07:43
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
- $705,000 — ry at his current annual base salary of $705,000, prorated through the Retirement Date.
Filing Documents
- bsx-20250829.htm (8-K) — 26KB
- 0000885725-25-000043.txt ( ) — 177KB
- bsx-20250829.xsd (EX-101.SCH) — 3KB
- bsx-20250829_def.xml (EX-101.DEF) — 15KB
- bsx-20250829_lab.xml (EX-101.LAB) — 27KB
- bsx-20250829_pre.xml (EX-101.PRE) — 16KB
- bsx-20250829_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 29, 2025, Jeffrey B. Mirviss informed Boston Scientific Corporation (the "Company") that he has decided to retire from his role as Executive Vice President and President, Peripheral Interventions effective as of December 1, 2025. Mr. Mirviss is expected to remain with the Company as a senior advisor from such time through February 27, 2026 (such date, or any earlier date, the "Retirement Date"). As a senior advisor, Mr. Mirviss will receive a base salary at his current annual base salary of $705,000, prorated through the Retirement Date. The Company expects to enter into a Retirement Agreement with Mr. Mirviss effective as of the Retirement Date, pursuant to which Mr. Mirviss will be entitled to payments and benefits that are materially consistent with those Mr. Mirviss is entitled to under, and subject to the terms and conditions of, the Company's Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and equity awards granted thereunder, respectively, each as previously filed with the U.S. Securities and Exchange Commission. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 4, 2025 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary